BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bridge Bio Announces First Patient Dosed in Phase 2a Trial of BBT-877 for Idiopathic Pulmonary Fibrosis Treatment

In the Phase 1 study in 2019, BBT-877, a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as...

April 13, 2023 | News

Altair to Showcase Pharmaceutical Process Optimization Technology at the Korea Pharm&Bio 2023

Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence (AI), will be exhibiting at Korea Pharm&Bio, Apri...

April 13, 2023 | News

Genexine's GX-E4 Phase 3 trial shows non-inferiority to Mircera for anemia treatment, presented at WCN2023

Kidneys are responsible for 90% of the EPO produced in our bodies. CKD-induced anemia is caused by the failure to produce EPO (erythropoietin) due to long-...

April 12, 2023 | News

BIORCHESTRA Hires David Oxley as Chief Business Officer to Expand Leadership Team

Adding additional strengths to the company's executive team, Mr. Oxley brings extensive experience in developing corporate strategy, leading cross-borders ...

April 06, 2023 | News

Standigm, Institut Pasteur Korea identify drug candidates for drug-resistant TB with grant

Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, and Korean non profit research institute Instit...

April 05, 2023 | News

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model

According to the company's explanation, bacteriophages have been mainly used for R&D on bacterial infectious diseases, but recently the scope of applic...

April 04, 2023 | News

Noul Co. Ltd's The RIGHT Foundation Begins Research and Development to Aid Malaria Control

Noul Co. Ltd (CEO : David Lim) announced that it has signed an agreement with The RIGHT Foundation to conduct a global clinical studies to determine t...

March 28, 2023 | News

Phase 1 trial of OLX72021of Treatment of Androgenic Alopecia has been approved for initiation in Australia

OliX will evaluate the safety and tolerability of OLX72021 in Phase 1 clinical trial Excellent hair growth effect is observed when used as external solu...

March 27, 2023 | News

Daewoong Pharma's Envlo files for product license in three ASEAN countries to enter global market

Submitted an NDA to Indonesia, Philippines and Thailand Signed the export contract in Brazil and Mexico in last ...

March 23, 2023 | News

Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution

Lunit set to launch Lunit INSIGHT DBT in the European market Lunit seeks FDA clearance, paving the way into the US market The MDR CE certification is...

March 21, 2023 | News

Samsung Biologics to build Plant 5 for Bio Campus II expansion.

The company plans to begin construction in the first half of 2023 and commence operations in 2025 As part of Samsung Biologics' second Bio Campus, ...

March 17, 2023 | News

Medit Launches New Occlusion Analyzer App for Quick and Easy Analysis

The Medit Occlusion Analyzer is a powerful tool that allows dental professionals to perform occlusion analysis quickly and easily without the need to ret...

March 09, 2023 | News

ExoCoBio Obtains GMP Licenses for Exosome Biopharmaceuticals and HA Dermal Fillers

ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. Cellosome™ HA fillers are expected to be approved ...

March 02, 2023 | News

GC Biopharma Acquires Catalyst Biosciences' Rare Disease Pipeline in Hematology

GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase ...

February 28, 2023 | News

Stay Connected